Advertisement

Topics

Merck and Pfizer’s immunotherapy fails in late-stage trial

11:25 EST 15 Feb 2018 | PharmaTimes

Bavencio (avelumab) has failed to meet its primary endpoint in a lung cancer trial

Original Article: Merck and Pfizer’s immunotherapy fails in late-stage trial

NEXT ARTICLE

More From BioPortfolio on "Merck and Pfizer’s immunotherapy fails in late-stage trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...